B. Riley initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $10 price target. The firm says its investment thesis centers on the company’s strategy to inactivate or degrade ...
Foghorn Therapeutics (FHTX) has received a new Buy rating, initiated by B.Riley Financial analyst, Kalpit Patel. Kalpit Patel’s rating is based on Foghorn Therapeutics’ innovative approach to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback